JPMorgan Chase & Co. Sells 186,539 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• JPMorgan Chase & Co. sold 186,539 shares, trimming its Centessa stake by 43.5% in Q3; it now holds 241,895 shares valued at about $5.87 million (≈0.18% of the company).
• Eli Lilly agreed to buy Centessa for $38 per share plus a potential CVR of up to $9, valuing the deal at roughly $6.3B up front and up to $7.8B with milestones, which has pushed CNTA shares above the $38 cash price and driven a 44% intraday gain.
• Insiders sold 349,073 shares worth about $9.43M in the last quarter (insiders now own 7.09%), and shareholder lawsuits have been filed alleging the deal may not deliver a fair price, which could delay or pressure the transaction terms.

JPMorgan Chase & Co. lessened its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 43.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 241,895 shares of the company's stock after selling 186,539 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.18% of Centessa Pharmaceuticals worth $5,866,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of CNTA. American Century Companies Inc. raised its holdings in shares of Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company's stock valued at $14,858,000 after purchasing an additional 37,954 shares during the last quarter. Royce & Associates LP acquired a new position in Centessa Pharmaceuticals during the third quarter worth $5,999,000. Eagle Health Investments LP bought a new position in Centessa Pharmaceuticals in the third quarter valued at $2,500,000. Foresite Capital Management VI LLC grew its position in Centessa Pharmaceuticals by 4.8% in the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company's stock valued at $31,865,000 after purchasing an additional 60,640 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $42,429,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the firm's stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares of the company's stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider directly owned 57,645 shares of the company's stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 349,073 shares of company stock worth $9,429,412. Company insiders own 7.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wolfe Research reissued a "peer perform" rating on shares of Centessa Pharmaceuticals in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial upped their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a "buy" rating in a report on Thursday, January 29th. Needham & Company LLC reissued a "hold" rating on shares of Centessa Pharmaceuticals in a research report on Tuesday. Finally, TD Cowen restated a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $40.00.

Centessa Pharmaceuticals News Summary

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

Centessa Pharmaceuticals Trading Up 44.0%

Centessa Pharmaceuticals stock opened at $39.72 on Wednesday. The stock has a 50-day simple moving average of $26.29 and a 200 day simple moving average of $25.24. The stock has a market capitalization of $5.80 billion, a P/E ratio of -21.70 and a beta of 1.55. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.